United Capital Financial Advisors’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.73M | Sell |
40,446
-2,586
| -6% | -$140K | 0.01% | 616 |
|
|
2026
Q1 | $2.7M | Sell |
43,032
-11,776
| -21% | -$942K | 0.02% | 488 |
|
|
2025
Q4 | $5.23M | Buy |
54,808
+3,338
| +6% | +$327K | 0.03% | 347 |
|
|
2025
Q3 | $5.03M | Buy |
51,470
+7,990
| +18% | +$827K | 0.04% | 308 |
|
|
2025
Q2 | $4.67M | Sell |
43,480
-414
| -0.9% | -$41.9K | 0.04% | 291 |
|
|
2025
Q1 | $4.43M | Buy |
43,894
+1,924
| +5% | +$194K | 0.04% | 289 |
|
|
2024
Q4 | $3.75M | Sell |
41,970
-528
| -1% | -$46.5K | 0.03% | 305 |
|
|
2024
Q3 | $3.56M | Sell |
42,498
-338
| -0.8% | -$26.6K | 0.03% | 317 |
|
|
2024
Q2 | $3.3M | Buy |
42,836
+2,670
| +7% | +$195K | 0.03% | 328 |
|
|
2024
Q1 | $2.75M | Sell |
40,166
-2,967
| -7% | -$191K | 0.02% | 374 |
|
|
2023
Q4 | $2.49M | Buy |
43,133
+38,906
| +920% | +$2.08M | 0.02% | 381 |
|
|
2023
Q3 | $223K | Sell |
4,227
-4,383
| -51% | -$230K | ﹤0.01% | 782 |
|
|
2023
Q2 | $466K | Sell |
8,610
-2,215
| -20% | -$116K | ﹤0.01% | 688 |
|
|
2023
Q1 | $542K | Buy |
10,825
+1,844
| +21% | +$86.9K | ﹤0.01% | 711 |
|
|
2022
Q4 | $416K | Buy |
8,981
+1,971
| +28% | +$85.3K | ﹤0.01% | 796 |
|
|
2022
Q3 | $272K | Sell |
7,010
-3,510
| -33% | -$141K | ﹤0.01% | 931 |
|
|
2022
Q2 | $392K | Buy |
10,520
+4,253
| +68% | +$173K | ﹤0.01% | 859 |
|
|
2022
Q1 | $278K | Buy |
+6,267
| New | +$272K | ﹤0.01% | 1007 |
|
|
2021
Q4 | – | Sell |
-7,151
| Closed | -$310K | – | 1206 |
|
|
2021
Q3 | $310K | Sell |
7,151
-5,332
| -43% | -$236K | ﹤0.01% | 996 |
|
|
2021
Q2 | $534K | Buy |
12,483
+724
| +6% | +$30.5K | ﹤0.01% | 844 |
|
|
2021
Q1 | $454K | Sell |
11,759
-1,636
| -12% | -$61.9K | ﹤0.01% | 872 |
|
|
2020
Q4 | $482K | Buy |
13,395
+3,444
| +35% | +$124K | ﹤0.01% | 858 |
|
|
2020
Q3 | $380K | Buy |
+9,951
| New | +$383K | ﹤0.01% | 897 |
|
|
2020
Q1 | – | Sell |
-20,834
| Closed | -$942K | – | 1214 |
|
|
2019
Q4 | $942K | Buy |
20,834
+12,109
| +139% | +$507K | 0.01% | 799 |
|
|
2019
Q3 | $355K | Sell |
8,725
-18,773
| -68% | -$795K | ﹤0.01% | 1040 |
|
|
2019
Q2 | $1.18M | Sell |
27,498
-1,354
| -5% | -$52.1K | 0.01% | 762 |
|
|
2019
Q1 | $1.11M | Buy |
28,852
+2,785
| +11% | +$106K | 0.01% | 755 |
|
|
2018
Q4 | $921K | Buy |
26,067
+3,086
| +13% | +$112K | 0.01% | 736 |
|
|
2018
Q3 | $885K | Buy |
22,981
+1,611
| +8% | +$56.3K | 0.01% | 817 |
|
|
2018
Q2 | $699K | Buy |
21,370
+220
| +1% | +$6.63K | 0.01% | 855 |
|
|
2018
Q1 | $578K | Buy |
21,150
+1,449
| +7% | +$39.4K | ﹤0.01% | 925 |
|
|
2017
Q4 | $488K | Sell |
19,701
-1,103
| -5% | -$30.4K | ﹤0.01% | 973 |
|
|
2017
Q3 | $607K | Sell |
20,804
-26,363
| -56% | -$728K | 0.01% | 904 |
|
|
2017
Q2 | $1.31M | Buy |
47,167
+14,548
| +45% | +$386K | 0.01% | 690 |
|
|
2017
Q1 | $811K | Buy |
32,619
+8,526
| +35% | +$207K | 0.01% | 802 |
|
|
2016
Q4 | $521K | Sell |
24,093
-38,295
| -61% | -$836K | 0.01% | 928 |
|
|
2016
Q3 | $1.49M | Buy |
62,388
+46,443
| +291% | +$1.11M | 0.01% | 667 |
|
|
2016
Q2 | $367K | Buy |
15,945
+3,075
| +24% | +$66.5K | ﹤0.01% | 988 |
|
|
2016
Q1 | $242K | Buy |
12,870
+303
| +2% | +$5.32K | ﹤0.01% | 1068 |
|
|
2015
Q4 | $232K | Buy |
+12,567
| New | +$225K | ﹤0.01% | 1093 |
|
|
2013
Q3 | – | Sell |
-41,957
| Closed | -$389K | – | 685 |
|
|
2013
Q2 | $389K | Buy |
+41,957
| New | +$356K | 0.01% | 550 |
|
Other funds holding BSX
United Capital Financial Advisors's BSX Position: Q2 2026 in Review
United Capital Financial Advisors reduced its Boston Scientific (BSX) stake by 6% in Q2 2026, selling an estimated $140K and leaving 40,446 shares worth $1.73M. The position accounts for 0.01% of the portfolio, ranked #616.
United Capital Financial Advisors first reported a position in BSX in Q2 2013 and has held it in 41 quarters since. The position peaked at $5.23M in Q4 2025. 1,470 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- United Capital Financial Advisors held 40,446 shares of Boston Scientific worth $1.73M as of Q2 2026.
- United Capital Financial Advisors sold 2,586 Boston Scientific shares in Q2 2026, an estimated $140K.
- Boston Scientific made up 0.01% of United Capital Financial Advisors's portfolio in Q2 2026, its #616 holding.
- United Capital Financial Advisors first reported a position in Boston Scientific in Q2 2013 and has held it in 41 quarters since.
- United Capital Financial Advisors's Boston Scientific position peaked at $5.23M in Q4 2025.
- 1,470 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on United Capital Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.